Daclizumab ELISA试剂盒(靶标：)

Daclizumab ELISA Kit

货号：RB9T37014614

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37014614

中文名称
Daclizumab ELISA试剂盒(靶标：)

英文名称
Daclizumab ELISA Kit

应用
ELISA

登录号
P01589

检测方法
Colorimetric

灵敏度
0.156 μg/ml

检测范围
0.31-5 μg/mL

回收率
80-120%

样本类型
Plasma, Serum

检测类型

Quantitative

背景信息

Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. Because CD25 blockade reduces IL-2 consumption by effector T cells, it increases IL-2 bioavailability allowing for greater interaction with the intermediate-affinity IL-2R, and therefore drives the expansion of CD56bright natural killer (NK) cells. Furthermore, there appears to be a direct correlation between CD56bright NK cell expansion and DAC HYP efficacy in reducing relapses and MRI evidence of disease activity in patients with RMS in phase II and phase III double-blind, placebo- and active comparator-controlled trials. Therapeutic efficacy was maintained during open-label extension studies. However, treatment was associated with an increased risk of rare adverse events, including cutaneous inflammation, autoimmune hepatitis, central nervous system Drug Reaction with Eosinophilia Systemic Symptoms (DRESS) syndrome, and autoimmune Glial Fibrillary Acidic Protein (GFAP) alpha immunoglobulin-associated encephalitis. As a result, DAC HYP was removed from clinical use in 2018. The lingering importance of DAC is that its use led to a deeper understanding of the underappreciated role of innate immunity in the potential treatment of autoimmune disease.

别名

BIIB019, DAC HYP, 152923-56-3

稳定性和储存

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

运输条件

2-8 ℃

For Research Use Only.